Sridhar Chaganti

University Hospitals Birmingham NHS Foundation Trust — United Kingdom

Medicine · Health Sciences

27h-index4.0kcitations155works8.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(77), CAR-T cell therapy research(49), Viral-associated cancers and disorders(39), Chronic Lymphocytic Leukemia Research(25), Cutaneous lymphoproliferative disorders research(19)

Publications154 total

Subgroup analysis based on prior treatment from the Phase 3 allele study of tabelecleucel for epstein-barr virus-driven post-transplant lymphoproliferative disease
Blood·2025Open Access
Autologous and allogeneic stem cell transplantation for ALK-positive anaplastic large cell lymphoma: An analysis of the EBMT lymphoma working party
Blood·2025Open Access
Analysis of immune parameters and effect of immunoglobulin replacement therapy on infection, survival and non-relapse mortality following CD19 CAR T-cell therapy
Blood·2025Open Access
An updated UK real-world analysis of factors affecting outcome following brexucabtagene autoleucel for relapsed or refractory adult acute lymphoblastic leukemia
Blood·2025Open Access
Initial results of a CRUK phase I/II, first in human trial of the CAR t-cell engager protein aleta-001 in patients who have received anti-CD19 CAR t-cell therapy for the treatment of b-cell malignancies
Blood·2025Open Access
Real-World use of brentuximab vedotin in CD30+ Cutaneous lymphomas: a retrospective analysis from a UK tertiary centre
European Journal of Cancer·2025
Clinical management of bispecific antibody therapy for lymphoma: A British Society for Haematology Good Practice Paper
British Journal of Haematology·2025Open Access
POSTER: CT-1086 Updated Clinical Results From the ALLELE Trial: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus (EBV)-Driven Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab Plus Chemotherapy
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: MM-196 Comparative Analysis of Pegfilgrastim and Filgrastim Use in Myeloma Autografts
Clinical Lymphoma Myeloma & Leukemia·2025
MM-196: Comparative Analysis of Pegfilgrastim and Filgrastim Use in Myeloma Autografts
Clinical Lymphoma Myeloma & Leukemia·2025
CT-1086: Updated Clinical Results From the ALLELE Trial: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus (EBV)-Driven Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab Plus Chemotherapy
Clinical Lymphoma Myeloma & Leukemia·2025
Allogeneic haematopoietic stem cell transplantation in advanced cutaneous T-cell lymphomas offers curative potential
Bone Marrow Transplantation·2025
PA26 Folliculotropic mycosis fungoides with large cell transformation in an adolescent patient
British Journal of Dermatology·2025Open Access
124 | Updated Results: Ph 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with EBV+ PTLD after Rituximab+/‐ Chemotherapy Failure
Hematological Oncology·2025Open Access
459 | OUTCOMES OF SECOND‐LINE AXICABTAGENE CILOLEUCEL FOR LARGE B‐CELL LYMPHOMA IN THE UK
Hematological Oncology·2025Open Access
15 | EARLY PET RESPONSE PREDICTS RISK OF RELAPSE AFTER 2L AXI‐CEL IN LARGE B‐CELL LYMPHOMA
Hematological Oncology·2025Open Access
326 | GLOFITAMAB AND EPCORITAMAB FOR LARGE B CELL LYMPHOMA IN 319 REAL WORLD PATIENTS: A RETROSPECTIVE UK ANALYSIS OF EFFICACY, TOLERABILITY AND PRACTICAL IMPLICATIONS
Hematological Oncology·2025Open Access
782 | GAME SET AND MATCH FOR CAR‐T IN DLBCL? WHY TREATMENT BIAS AGAINST BISPECIFIC ANTIBODIES MAY MAKE MATCHED REAL‐WORLD COMPARISONS UNINTERPRETABLE
Hematological Oncology·2025Open Access
Efficacy and safety outcomes of obecabtagene autoleucel (obe-cel) stratified by age in patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
Journal of Clinical Oncology·2025· 2 cited
Management of relapsed or refractory large B‐cell lymphoma: A British Society for Haematology Guideline
British Journal of Haematology·2025· 4 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Christopher P. Fox(11), Claire Roddie(10), Armin Ghobadi(9), Kate Cwynarski(9), Tobias Menne(8), Wendy Osborne(7), Maeve O’Reilly(7), Andrea Kühnl(7), Andrew Bell(7), Eleni Tholouli(6), Caroline Besley(6), Robin Sanderson(6), Alan B. Rickinson(6), David Burns(6), Anna Sureda(5), Pam McKay(5), Kim Linton(5), Ram Malladi(5), Andrew Stevens(5), Julia Scarisbrick(5)